ReviewFrontiers in pharmacology2026

Prodigiosin in glioblastoma: mechanistic pharmacology and rationale for its development as a radiosensitiser.

Hansika RayPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.